DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claim Rejections - 35 USC § 102
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claim(s) 17 and 19-20 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Wdowiak et al. (Bioconjugate Chemistry, 2021) (Wdowiak).
Regarding claim 17, Wdowiak teaches a method for characterizing a protein of interest in a first sample (abstract), the method comprising:
forming an alkylated product by either: alkylating the protein of interest with a carbon 13 substituted NEM analog to form a 13C-NEM analog alkylated protein of interest (page 1663, par 6) or alkylating a peptide digest of the protein of interest with a carbon 13 substituted NEM analog to form a 13CNEM analog alkylated peptide digest.
Since claim 17 recites alternative alkylation methods connected by “or,” disclosure of the first alternative is sufficient to satisfy the claimed limitation. Wdowiak expressly teaches alkylating a protein with the carbon-13 substituted ICMAT-3 (16*) to form an alkylated protein product.
Regarding claim 19, Wdowiak teaches further comprising: subjecting the alkylated product to analysis using liquid chromatography-mass spectrometry to characterize the protein of interest (page 1664. par 2),
Regarding claim 20, Wdowiak teaches the alkylated product obtained by the method of claim 17 (page 1663, par 6).
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
Claim(s) 18 is/are rejected under 35 U.S.C. 103 as being unpatentable over Wdowiak et al. (Bioconjugate Chemistry, 2021) (Wdowiak) in view of Schueffl et al. (Chemical Science, 2021) (Schueffl).
Regarding claim 18, Wdowiak teaches alkylating proteins with carbon-13-labeled ICMAT-3 (16*) (page 1663, “Labeling of Lysozyme Standards”: “DMSO solutions of ICMATs (5 mM) (7, 7*, 16, and 16*) were stored at −20 °C. Aliquots of reduced lysozyme solution (400 μL, containing 40 μg lysozyme) were alkylated by the addition of 16 μL of 5 mM ICMAT solution (i.e., each ICMAT was added to a separate aliquot of reduced lysozyme at a ratio of 2 nmol ICMAT/μg lysozyme), followed by vigorous vortexing at room temperature for 1 h.”).
However, Wdowiak does not expressly disclose wherein the carbon 13 substituted NEM analog comprises ¹³C₄-maleimide, because Wdowiak's ICMAT-3 (16*) contains a ¹³C₆-labeled phenylene linker rather than a ¹³C₄-labeled maleimide ring (page 1655, Scheme 2).
Schueffl teaches carbon-13 labeling of all four carbon atoms of a maleimide ring (page 12595: “To this end, the maleimide moiety and the diaminocyclohexane (DACH) ligand were ¹³C- and ²H-labeled, respectively (Fig. 5A). In more detail, ¹³C₇,¹⁵N-labelled maleimidopropionic acid was synthesized from β-alanine–¹³C₃,¹⁵N and maleic anhydride-¹³C₄, while the deuterium-labelled oxaliplatin was synthesized in six steps starting from D10-cyclohexene based on a protocol for similar compounds.”; see also Figure 5A, page 12596) (Schueffl's labeled maleimide derivative contains four carbon-13 atoms in its maleimide ring).
It would have been obvious to one of ordinary skill in the art before the effective filing date to modify Wdowiak's carbon-13-labeled ICMAT-3 by incorporating the ¹³C₄-labeled maleimide ring taught by Schueffl, motivated to improve mass-spectrometric discrimination of isotope-labeled peptides by providing additional mass separation while retaining the thiol-reactive maleimide functionality. Wdowiak teaches that carbon-13 labeling provides favorable chromatographic coelution of corresponding light- and heavy-labeled peptides (page 1657, “Evaluation of 12C/13C-Labeled ICMAT-3”). Schueffl demonstrates that carbon-13 atoms can be incorporated into the maleimide ring itself (page 12595 and Figure 5A). A skilled artisan would have reasonably expected that substituting carbon-13 for naturally occurring carbon in Wdowiak's maleimide ring would preserve its chemical connectivity and thiol-alkylating functionality while increasing the mass difference detectable by mass spectrometry.
Allowable Subject Matter
Claim 1-16 are allowed.
The following is a statement of reasons for the indication of allowable subject matter: While Robotham et al. and Pu et al. disclose differential labeling of free thiols using paired light and heavy isotope-labeled NEM reagents followed by enzymatic digestion and LC-MS analysis, Wdowiak et al. disclose corresponding light and heavy isotope-labeled maleimide analogs, and Gao et al. disclose isotope labeling of peptides after enzymatic digestion, the prior art of record, either alone or in combination, fails to teach or suggest alkylating a protein of interest with a NEM analog or its heavy isotope-substituted form, digesting the alkylated protein with at least one digestive enzyme to form a peptide digest, and subsequently alkylating the peptide digest with the corresponding differential alkylating agent, followed by LC-MS analysis to quantify site-specific free thiols in the original sample. In particular, the prior art does not teach or suggest separating the paired differential alkylation steps by enzymatic digestion in the claimed sequence.
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to XIAOYUN R XU, Ph. D. whose telephone number is (571)270-5560. The examiner can normally be reached M-F 8am-5pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Lyle Alexander can be reached at 571-272-1254. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/XIAOYUN R XU, Ph.D./ Primary Examiner, Art Unit 1797